Nadeem R Abu-Rustum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2245513/publications.pdf

Version: 2024-02-01

208 papers

13,083 citations

23567 58 h-index 27406 106 g-index

211 all docs

211 docs citations

211 times ranked

9517 citing authors

#	Article	IF	Citations
1	Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. JCO Oncology Practice, 2022, 18, 201-209.	2.9	34
2	TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition. Modern Pathology, 2022, 35, 117-127.	5 . 5	16
3	Patient-reported benefit from proposed interventions to reduce financial toxicity during cancer treatment. Supportive Care in Cancer, 2022, 30, 2713-2721.	2.2	28
4	ASO Visual Abstract: Enhanced PAtient Clinical Streamlining (EPACS)â€"Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits. Annals of Surgical Oncology, 2022, 29, 1805-1806.	1.5	0
5	Enhanced PAtient Clinical Streamlining (EPACS): Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits. Annals of Surgical Oncology, 2022, 29, 1789-1796.	1.5	1
6	Clear Cell Carcinoma (CCC) of the Cervix Is a Human Papillomavirus (HPV)-independent Tumor Associated With Poor Outcome. American Journal of Surgical Pathology, 2022, 46, 765-773.	3.7	12
7	Assessment of wound perfusion with near-infrared angiography: A prospective feasibility study. Gynecologic Oncology Reports, 2022, 40, 100940.	0.6	1
8	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
9	Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma. Gynecologic Oncology, 2022, 165, 287-292.	1.4	9
10	Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. JCO Clinical Cancer Informatics, 2022, 6, e2100154.	2.1	2
11	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. Gynecologic Oncology, 2022, 165, 239-247.	1.4	9
12	Genomic landscape of endometrial carcinomas of no specific molecular profile. Modern Pathology, 2022, 35, 1269-1278.	5 . 5	33
13	Gastric-type adenocarcinoma of the cervix in patients with Peutz-Jeghers syndrome: a systematic review of the literature with proposed screening guidelines. International Journal of Gynecological Cancer, 2022, 32, 79-88.	2.5	10
14	Risk factors for financial toxicity in patients with gynecologic cancer. American Journal of Obstetrics and Gynecology, 2022, 226, 817.e1-817.e9.	1.3	20
15	Oncologists' Attitudes Toward Cancer Care Affordability. JAMA Network Open, 2022, 5, e227863.	5.9	3
16	Recurrent <i>WWTR1</i> <scp>S89W</scp> mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix. Journal of Pathology, 2022, 257, 635-649.	4.5	2
17	Clinical correlation of lymphovascular invasion and Silva pattern of invasion in early-stage endocervical adenocarcinoma: proposed binary Silva classification system. Pathology, 2022, 54, 548-554.	0.6	5
18	Primary characteristics and outcomes of newly diagnosed low-grade endometrial stromal sarcoma. International Journal of Gynecological Cancer, 2022, 32, 882-890.	2.5	4

#	Article	IF	CITATIONS
19	Demographic shifts associated with implementation of evidence-based guidelines for ovarian conservation in patients with endometrioid endometrial cancer. International Journal of Gynecological Cancer, 2022, 32, 1141-1146.	2.5	1
20	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. Molecular Oncology, 2021, 15, 1024-1039.	4.6	21
21	Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecologic Oncology, 2021, 160, 51-55.	1.4	2
22	FIGO 2018 stage IB endocervical adenocarcinomas: an international study of outcomes informed by prognostic biomarkers. International Journal of Gynecological Cancer, 2021, 31, 177-184.	2.5	11
23	The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome. Gynecologic Oncology, 2021, 160, 99-105.	1.4	10
24	Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes. Modern Pathology, 2021, 34, 994-1007.	5.5	19
25	Clinicopathologic and Genomic Analysis of <i>TP53</i> Hutated Endometrial Carcinomas. Clinical Cancer Research, 2021, 27, 2613-2623.	7.0	49
26	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. International Journal of Gynecological Cancer, 2021, 31, 647-655.	2.5	28
27	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. Gynecologic Oncology, 2021, 160, 696-703.	1.4	2
28	Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases. Modern Pathology, 2021, 34, 1570-1587.	5.5	57
29	Effect of a Predictive Model on Planned Surgical Duration Accuracy, Patient Wait Time, and Use of Presurgical Resources. JAMA Surgery, 2021, 156, 315.	4.3	37
30	Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma. Histopathology, 2021, 79, 176-186.	2.9	4
31	Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer. Gynecologic Oncology, 2021, 161, 463-469.	1.4	11
32	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. Gynecologic Oncology, 2021, 161, 535-544.	1.4	16
33	Case report: Sentinel lymph node mapping of endometrial carcinoma occurring in uterine didelphys. Gynecologic Oncology Reports, 2021, 36, 100769.	0.6	2
34	Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. Gynecologic Oncology, 2021, 161, 545-552.	1.4	8
35	Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. Gynecologic Oncology, 2021, 163, 36-40.	1.4	18
36	Clinical outcomes of patients with endometrioid epithelial ovarian cancer following surgical treatment. Journal of Surgical Oncology, 2021, 124, 846-851.	1.7	0

#	Article	IF	CITATIONS
37	Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction - A proposed management algorithm. Gynecologic Oncology, 2021, 162, 262-267.	1.4	12
38	Non-exenterative surgical management of recurrent endometrial carcinoma. Gynecologic Oncology, 2021, 162, 268-276.	1.4	5
39	Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. Gynecologic Oncology, 2021, 162, 345-352.	1.4	8
40	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. Gynecologic Oncology Reports, 2021, 37, 100831.	0.6	4
41	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	1.6	83
42	Diagnosis and management of an endometrial cancer patient with Cowden syndrome. Gynecologic Oncology, 2021, 163, 14-21.	1.4	6
43	Quaternary and beyond cytoreduction: An updated and expanded analysis. Gynecologic Oncology Reports, 2021, 37, 100851.	0.6	1
44	Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort. Gynecologic Oncology, 2021, 163, 294-298.	1.4	9
45	ConCerv: a prospective trial of conservative surgery for low-risk early stage cervical cancer, by Schmeler <i>et al</i> . International Journal of Gynecological Cancer, 2021, 31, 1326-1327.	2.5	1
46	Paradigm shifts in gynecologic oncology. International Journal of Gynecological Cancer, 2021, 31, ijgc-2021-003108.	2.5	2
47	Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. International Journal of Gynecological Cancer, 2021, 31, 222-231.	2.5	2
48	Horizontal tumor extent (HZTE) has limited prognostic significance in 2018 FIGO stage I endocervical adenocarcinoma (ECA): a retrospective study of 416 cases. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	2.5	4
49	European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 1508-1529.	2.5	13
50	ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment. Modern Pathology, 2021, , .	5.5	5
51	Positron Lymphography via Intracervical ¹⁸ F-FDG Injection for Presurgical Lymphatic Mapping in Cervical and Endometrial Malignancies. Journal of Nuclear Medicine, 2020, 61, 1123-1130.	5.0	8
52	Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. Gynecologic Oncology, 2020, 156, 591-597.	1.4	54
53	Identification of recurrent FHL2-GL12 oncogenic fusion in sclerosing stromal tumors of the ovary. Nature Communications, 2020, 11, 44.	12.8	34
54	Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma. Gynecologic Oncology, 2020, 156, 70-76.	1.4	37

#	Article	IF	CITATIONS
55	Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma. Gynecologic Oncology, 2020, 156, 62-69.	1.4	43
56	Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecologic Oncology, 2020, 156, 194-202.	1.4	35
57	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. Gynecologic Oncology, 2020, 156, 147-153.	1.4	61
58	Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. JCO Precision Oncology, 2020, 4, 1217-1223.	3.0	1
59	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. Scientific Reports, 2020, 10, 17769.	3.3	35
60	DNA Mismatch Repair–deficient Endometrial Carcinosarcomas Portend Distinct Clinical, Morphologic, and Molecular Features Compared With Traditional Carcinosarcomas. American Journal of Surgical Pathology, 2020, 44, 1573-1579.	3.7	22
61	Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget's Disease of the Vulva. JCO Precision Oncology, 2020, 4, 1054-1060.	3.0	12
62	Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. Gynecologic Oncology, 2020, 159, 66-71.	1.4	12
63	Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. International Journal of Gynecological Cancer, 2020, 30, 1162-1168.	2.5	6
64	Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. Cancers, 2020, 12, 3403.	3.7	24
65	A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel) Tj ETQq1 1 1627-1632.	. 0.784314 2.5	, 4 rgBT /Over <mark>lo</mark> c
66	Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study. Gynecologic Oncology, 2020, 159, 187-194.	1.4	12
67	Radical Trachelectomy for the Treatment of Early-Stage Cervical Cancer. Obstetrics and Gynecology, 2020, 136, 533-542.	2.4	61
68	Sentinel lymph node mapping in endometrial cancer – areas where further research is needed. International Journal of Gynecological Cancer, 2020, 30, 283-284.	2.5	15
69	Surveillance patterns of cervical cancer patients treated with conization alone. International Journal of Gynecological Cancer, 2020, 30, 1129-1135.	2.5	3
70	A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. Gynecologic Oncology, 2020, 158, 608-613.	1.4	23
71	Evolution and outcomes of sentinel lymph node mapping in vulvar cancer. International Journal of Gynecological Cancer, 2020, 30, 383-386.	2.5	25
72	Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary. Modern Pathology, 2020, 33, 1606-1617.	5 . 5	38

#	Article	IF	CITATIONS
73	The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. Gynecologic Oncology, 2020, 158, 397-401.	1.4	7
74	Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors. Cancer Research, 2020, 80, 3466-3479.	0.9	29
75	Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma. Gynecologic Oncology, 2020, 157, 619-623.	1.4	32
76	Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. Annals of Surgical Oncology, 2020, 27, 3772-3780.	1.5	16
77	IGCS Intraoperative Technology Taskforce. Update on near infrared imaging technology: beyond white light and the naked eye, indocyanine green and near infrared technology in the treatment of gynecologic cancers. International Journal of Gynecological Cancer, 2020, 30, 670-683.	2.5	18
78	Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. Gynecologic Oncology, 2020, 159, 418-425.	1.4	7
79	Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Gynecologic Oncology, 2019, 154, 516-523.	1.4	62
80	Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: Comparison of comprehensive surgical staging and sentinel lymph node algorithm. Gynecologic Oncology, 2019, 155, 177-185.	1.4	38
81	Conservative management of cervical cancer in pregnancy. International Journal of Gynecological Cancer, 2019, 29, 434-438.	2.5	0
82	Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 64-84.	4.9	700
83	Factors influencing the adoption of the sentinel lymph node technique for endometrial cancer staging: an international survey of gynecologic oncologists. International Journal of Gynecological Cancer, 2019, 29, 60-67.	2.5	43
84	Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. Gynecologic Oncology, 2019, 154, 333-337.	1.4	14
85	Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer. Gynecologic Oncology, 2019, 154, 60-64.	1.4	35
86	When surgical innovation and payment systems collide: The sentinel lymph node story. Gynecologic Oncology, 2019, 153, 215-216.	1.4	1
87	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15.	3.0	7
88	Clinical Outcomes of HPV-associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC). American Journal of Surgical Pathology, 2019, 43, 466-474.	3.7	84
89	Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma. Brachytherapy, 2019, 18, 38-43.	0.5	8
90	Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 170-199.	4.9	488

#	Article	IF	Citations
91	Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 201-209.	4.9	75
92	Prospective Comparative Study of Laparoscopic Narrow Band Imaging (NBI) Versus Standard Imaging in Gynecologic Oncology. Annals of Surgical Oncology, 2018, 25, 984-990.	1.5	12
93	Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center. Gynecologic Oncology, 2018, 149, 43-48.	1.4	10
94	International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers. International Journal of Gynecological Cancer, 2018, 28, 915-924.	2.5	17
95	ASO Author Reflections: Narrow-Band Imaging: A Novel Imaging Method in Minimally Invasive Surgery. Annals of Surgical Oncology, 2018, 25, 880-881.	1.5	0
96	Tailoring adjuvant treatment in patients with uterine cancer – Authors' reply. Lancet Oncology, The, 2018, 19, e656.	10.7	1
97	Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment. Gynecologic Oncology, 2018, 151, 395-400.	1.4	14
98	Role of imaging in the routine management of endometrial cancer. International Journal of Gynecology and Obstetrics, 2018, 143, 109-117.	2.3	59
99	Sentinel Lymph Node Mapping for Endometrial Cancer. , 2018, , 141-148.		0
100	Surgical treatment of "intermediate risk―lymph node negative cervical cancer patients without adjuvant radiotherapyâ€"A retrospective cohort study and review of the literature. Gynecologic Oncology, 2018, 151, 438-443.	1.4	46
101	Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy. Gynecologic Oncology, 2018, 151, 235-242.	1.4	63
102	Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer. Gynecologic Oncology, 2018, 151, 287-293.	1.4	23
103	Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. Gynecologic Oncology, 2018, 150, 127-135.	1.4	41
104	Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. Gynecologic Oncology, 2018, 150, 44-49.	1.4	30
105	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical Cancer Research, 2018, 24, 5939-5947.	7.0	100
106	Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?. Gynecologic Oncology, 2018, 151, 24-31.	1.4	64
107	Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. Lancet Oncology, The, 2018, 19, 1394-1403.	10.7	229
108	A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. Gynecologic Oncology, 2017, 145, 230-235.	1.4	43

#	Article	IF	CITATIONS
109	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. Gynecologic Oncology, 2017, 145, 15-20.	1.4	55
110	Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping. Annals of Surgical Oncology, 2017, 24, 1965-1971.	1.5	47
111	A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecologic Oncology, 2017, 145, 27-31.	1.4	95
112	A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer. International Journal of Gynecological Cancer, 2017, 27, 743-747.	2. 5	42
113	Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management. Abdominal Radiology, 2017, 42, 2488-2512.	2.1	30
114	Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. Gynecologic Oncology, 2017, 146, 263-267.	1.4	33
115	Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecologic Oncology, 2017, 146, 405-415.	1.4	298
116	Sexual health needs and educational intervention preferences for women with cancer. Breast Cancer Research and Treatment, 2017, 165, 77-84.	2.5	86
117	Riskâ€reducing salpingectomy: Let us be opportunistic. Cancer, 2017, 123, 1714-1720.	4.1	31
118	Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture Analysis. European Radiology, 2017, 27, 2903-2915.	4.5	128
119	Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. Gynecologic Oncology, 2017, 147, 541-548.	1.4	82
120	Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer. Gynecologic Oncology, 2017, 147, 371-374.	1.4	7
121	Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery. Gynecologic Oncology, 2017, 147, 115-119.	1.4	31
122	2017 Update on the Querleu–Morrow Classification of Radical Hysterectomy. Annals of Surgical Oncology, 2017, 24, 3406-3412.	1.5	162
123	A call to standardize our approach to fertility-sparing surgery in patients with gynecologic cancers. Gynecologic Oncology, 2017, 147, 491-492.	1.4	3
124	Robotically Assisted Laparoscopic Ovarian Transposition in Women with Lower Gastrointestinal Cancer Undergoing Pelvic Radiotherapy. Annals of Surgical Oncology, 2017, 24, 251-256.	1.5	14
125	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. JAMA Oncology, 2016, 2, 1434.	7.1	189
126	Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecologic Oncology Reports, 2016, 16, 42-46.	0.6	40

#	Article	IF	CITATIONS
127	Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery. Annals of Surgical Oncology, 2016, 23, 2522-2528.	1.5	69
128	Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy. Gynecologic Oncology, 2016, 143, 18-21.	1.4	19
129	Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. Breast Cancer Research and Treatment, 2016, 160, 447-456.	2.5	16
130	Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. Gynecologic Oncology, 2016, 142, 217-224.	1.4	42
131	A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's disease. Gynecologic Oncology, 2016, 142, 139-143.	1.4	57
132	Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecologic Oncology, 2016, 140, 436-442.	1.4	97
133	Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer. Annals of Surgical Oncology, 2016, 23, 2192-2198.	1.5	43
134	Sentinel Lymph Node Mapping in Endometrial Cancer: An Update. Oncologist, 2016, 21, 461-466.	3.7	61
135	Low-Volume Lymph Node Metastasis Discovered During Sentinel Lymph Node Mapping for Endometrial Carcinoma. Annals of Surgical Oncology, 2016, 23, 1653-1659.	1.5	114
136	Herniation formation in women undergoing robotically assisted laparoscopy or laparotomy for endometrial cancer. Gynecologic Oncology, 2016, 140, 383-386.	1.4	10
137	Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. Gynecologic Oncology, 2016, 140, 394-399.	1.4	139
138	Is It Time to Centralize Ovarian Cancer Care in the United States?. Annals of Surgical Oncology, 2016, 23, 989-993.	1.5	44
139	Diagnostic Performance of Computed Tomography for Preoperative Staging of Patients with Non-endometrioid Carcinomas of the Uterine Corpus. Annals of Surgical Oncology, 2016, 23, 1271-1278.	1.5	5
140	Second-Opinion Interpretations of Gynecologic Oncologic MRI Examinations by Sub-Specialized Radiologists Influence Patient Care. European Radiology, 2016, 26, 2089-2098.	4.5	47
141	Endometrial cancer. Lancet, The, 2016, 387, 1094-1108.	13.7	1,213
142	Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. Annals of Surgical Oncology, 2016, 23, 196-202.	1.5	86
143	Uterine Sarcoma, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1321-1331.	4.9	58
144	Cervical Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 395-404.	4.9	250

#	Article	IF	CITATIONS
145	The role of systemic chemotherapy in the management of granulosa cell tumors. Gynecologic Oncology, 2015, 136, 505-511.	1.4	45
146	Sentinel lymph node biopsy in the management of gynecologic cancer. Current Opinion in Obstetrics and Gynecology, 2015, 27, 66-72.	2.0	69
147	Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. Gynecologic Oncology, 2015, 138, 246-251.	1.4	71
148	Sentinel Lymph Node Mapping for Endometrial Cancer. , 2015, , 305-313.		2
149	Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma. Gynecologic Oncology, 2014, 135, 49-53.	1.4	25
150	Update on sentinel node mapping in uterine cancer: 10â€year experience at <scp>M</scp> emorial <scp>S</scp> loan– <scp>K</scp> ettering <scp>C</scp> ancer <scp>C</scp> enter. Journal of Obstetrics and Gynaecology Research, 2014, 40, 327-334.	1.3	61
151	Histological features associated with occult lymph node metastasis in <scp>FIGO</scp> clinical stage <scp>I</scp> , grade <scp>I</scp> endometrioid carcinoma. Histopathology, 2014, 64, 389-398.	2.9	40
152	Cervical Conization and Sentinel Lymph Node Mapping in the Treatment of Stage I Cervical Cancer: Is Less Enough?. International Journal of Gynecological Cancer, 2014, 24, 113-117.	2.5	47
153	Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. Gynecologic Oncology, 2014, 133, 274-277.	1.4	246
154	A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecologic Oncology, 2014, 134, 455-461.	1.4	180
155	Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. European Journal of Radiology, 2014, 83, 1169-1176.	2.6	109
156	Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer. Gynecologic Oncology, 2014, 134, 297-301.	1.4	11
157	Sentinel Lymph Node Mapping for Endometrial Cancer: A Modern Approach to Surgical Staging. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 288-297.	4.9	164
158	Uterine Neoplasms, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 248-280.	4.9	113
159	Sentinel lymph node mapping with pathologic ultrastaging: A valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecologic Oncology, 2013, 131, 714-719.	1.4	76
160	The Increasing Credibility of Sentinel Lymph Node Mapping in Endometrial Cancer. Annals of Surgical Oncology, 2013, 20, 353-354.	1.5	41
161	Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer. Gynecologic Oncology, 2013, 128, 28-33.	1.4	11
162	Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. Gynecologic Oncology, 2013, 130, 452-456.	1.4	87

#	Article	IF	CITATIONS
163	Expanding the Indications for Radical Trachelectomy. International Journal of Gynecological Cancer, 2013, 23, 1092-1098.	2.5	77
164	Redefining Stage I Endometrial Cancer: Incorporating Histology, a Binary Grading System, Myometrial Invasion, and Lymph Node Assessment. International Journal of Gynecological Cancer, 2013, 23, 1620-1628.	2.5	25
165	Pathologic Ultrastaging Improves Micrometastasis Detection in Sentinel Lymph Nodes During Endometrial Cancer Staging. International Journal of Gynecological Cancer, 2013, 23, 964-970.	2.5	223
166	Prognostic Value of Lymph Node Ratio and Clinicopathologic Parameters in Patients Diagnosed With Stage IIIC Endometrial Cancer. Obstetrics and Gynecology, 2012, 119, 1210-1218.	2.4	36
167	An International Series on Abdominal Radical Trachelectomy: 101 Patients and 28 Pregnancies. International Journal of Gynecological Cancer, 2012, 22, 1251-1257.	2.5	98
168	The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: Beyond removal of blue nodes. Gynecologic Oncology, 2012, 125, 531-535.	1.4	353
169	External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gynecologic Oncology, 2012, 125, 526-530.	1.4	19
170	Clinical Approach to Diagnosis and Management of Cancer of the Cervix and Vulva. Surgical Pathology Clinics, 2011, 4, 1-16.	1.7	1
171	Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecologic Oncology, 2011, 122, 275-280.	1.4	146
172	The Revised 2009 FIGO Staging System for Endometrial Cancer: Should the 1988 FIGO Stages IA and IB Be Altered?. International Journal of Gynecological Cancer, 2011, 21, 511-516.	2.5	60
173	Fertility-Sparing Surgery in Early-Stage Cervical Cancer: Indications and Applications. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1435-1438.	4.9	44
174	Radical abdominal trachelectomy for stage IB1 cervical cancer at 15-week gestation. Gynecologic Oncology, 2010, 116, 151-152.	1.4	50
175	The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecologic Oncology, 2010, 119, 38-42.	1.4	162
176	Micrometastasis of endometrial cancer to sentinel lymph nodes: Is it an artifact of uterine manipulation?. Gynecologic Oncology, 2010, 119, 496-499.	1.4	35
177	Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. Journal of Clinical Oncology, 2009, 27, 2066-2072.	1.6	119
178	Sentinel Lymph Node Biopsy in the Management of Vulvar Carcinoma, Cervical Cancer, and Endometrial Cancer. Oncologist, 2009, 14, 695-705.	3.7	36
179	Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: A comparison of surgical and pathologic outcomes. Gynecologic Oncology, 2009, 112, 73-77.	1.4	104
180	Sentinel lymph node mapping for grade 1 endometrial cancer: Is it the answer to the surgical staging dilemma?. Gynecologic Oncology, 2009, 113, 163-169.	1.4	202

#	Article	IF	Citations
181	Pediatric radical abdominal trachelectomy for solitary fibrous tumor of the uterine cervix. Gynecologic Oncology, 2009, 115, 302-305.	1.4	12
182	The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecologic Oncology, 2009, 115, 236-238.	1.4	164
183	Improving sentinel lymph node detection rates in endometrial cancer: How many cases are needed?. Gynecologic Oncology, 2009, 115, 453-455.	1.4	134
184	Pediatric radical abdominal trachelectomy for anaplastic embryonal rhabdomyosarcoma of the uterine cervix: an alternative to radical hysterectomy. Journal of Pediatric Surgery, 2009, 44, 862-867.	1.6	25
185	Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?. American Journal of Obstetrics and Gynecology, 2008, 198, 457.e1-457.e6.	1.3	82
186	What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma?. Gynecologic Oncology, 2008, 111, 46-48.	1.4	33
187	A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage l–IV uterine carcinosarcoma. Gynecologic Oncology, 2008, 111, 249-254.	1.4	68
188	Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. Gynecologic Oncology, 2008, 111, 261-264.	1.4	142
189	Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. Gynecologic Oncology, 2008, 111, 255-260.	1.4	174
190	Techniques of sentinel lymph node identification for early-stage cervical and uterine cancer. Gynecologic Oncology, 2008, 111, S44-S50.	1.4	58
191	Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecologic Oncology, 2008, 111, 244-248.	1.4	69
192	Sentinel lymph node identification for early-stage cervical cancer. Gynecologic Oncology, 2007, 104, 2-4.	1.4	5
193	Transperitoneal laparoscopic staging with aortic and pelvic lymph node dissection for gynecologic malignancies. Gynecologic Oncology, 2007, 104, 5-8.	1.4	11
194	Fertility-sparing radical abdominal trachelectomy for cervical carcinoma. Gynecologic Oncology, 2007, 104, 56-59.	1.4	24
195	Twelve-year experience in the management of endometrial cancer: A change in surgical and postoperative radiation approaches. Gynecologic Oncology, 2007, 105, 150-156.	1.4	83
196	Observations on the role of circumflex iliac node resection and the etiology of lower extremity lymphedema following pelvic lymphadenectomy for gynecologic malignancy. Gynecologic Oncology, 2007, 106, 4-5.	1.4	56
197	Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer. Gynecologic Oncology, 2007, 107, 66-70.	1.4	23
198	Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecologic Oncology, 2006, 103, 31-34.	1.4	87

#	ARTICLE	IF	CITATIONS
199	The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: A 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecologic Oncology, 2006, 103, 714-718.	1.4	347
200	Cystoscopic temporary ureteral catheterization during radical vaginal and abdominal trachelectomy. Gynecologic Oncology, 2006, 103, 729-731.	1.4	26
201	Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: Technique and review of the literature. Gynecologic Oncology, 2006, 103, 807-813.	1.4	138
202	Pediatric radical abdominal trachelectomy for cervical clear cell carcinoma: A novel surgical approach. Gynecologic Oncology, 2005, 97, 296-300.	1.4	36
203	Transfusion utilization during adnexal or peritoneal cancer surgery: Effects on symptomatic venous thromboembolism and survival. Gynecologic Oncology, 2005, 99, 320-326.	1.4	47
204	A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible?. Gynecologic Oncology, 2004, 95, 534-538.	1.4	143
205	Subcutaneous Tumor Implantation After Laparoscopic Procedures in Women With Malignant Disease. Obstetrics and Gynecology, 2004, 103, 480-487.	2.4	70
206	The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer. Gynecologic Oncology, 2003, 90, 431-434.	1.4	36
207	Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy. Gynecologic Oncology, 2003, 91, 402-409.	1.4	196
208	Genomic determinants of early recurrences in low-stage low-grade endometrioid endometrial carcinoma. Journal of the National Cancer Institute, 0, , .	6.3	1